The ongoing company has several steady and soluble single-chain antibody fragments in development, with its most advanced product candidate progressed into Stage I and II research relating to the treatment of inflammatory ocular illnesses. Dominik Escher, chief executive officer of ESBATech. Substantially all of the employees of ESBATech shall join Alcon upon the finalization of the acquisition. The privileges to the technology and products for application beyond ophthalmology will become retained by the prior shareholders of ESBATech and spun off right into a separate new firm, Delenex Therapeutics AG.. Alcon to obtain ESBATech AG Alcon announced today that it has entered into a definitive contract to acquire ESBATech AG, a Swiss biotechnology business. Alcon will pay ESBATech shareholders $150 million in money at closing, plus contingent obligations as high as $439 million based upon the achievement of long term research and development milestones that might be expected to create value for Alcon.A visual chart circulating on Reddit, for example, reveals that a mere 10 corporations control almost all major food brands these days. 90 % of the American mainstream mass media, according to a recently available Frugal Dad ‘infographic,’ can be owned by just six companies now, as opposed to about 50 back in 1983. And the amount of major American banking institutions in operation provides diminished from about 37 back in the 1990s to simply four today.